The main idea is how the body eliminates drugs, with the kidneys handling the majority of excretion. Most drugs are cleared from the body primarily by the kidneys into the urine. This happens as the kidneys filter freely circulating drug through the glomeruli, then may actively secrete additional drug into the filtrate in the proximal tubule, and, depending on a drug’s properties, may be reabsorbed later in the nephron. Factors like molecular size, polarity, protein binding, and the drug’s ionization state influence how much is excreted renally. For example, altering urine pH can change ionization and promote “ion trapping” to enhance excretion of weak acids or bases. While some drugs are eliminated via the GI tract through bile into feces, or by other routes such as the lungs for volatile substances or tiny amounts through sweat, these are not the primary pathways for most drugs.

The essential idea is that drugs must prove their safety (and effectiveness) before they reach patients. The FDA reviews data from laboratory studies and clinical trials to determine whether the benefits of a new drug outweigh the risks, and to ensure the manufacturing process and labeling clearly communicate who should use the drug, how it’s dosed, and what risks to watch for. Only after this thorough premarketing evaluation is the drug approved for marketing. After approval, the FDA continues to monitor safety in the real world, but the question highlights the premarketing determination: the FDA is authorized to determine safety before a drug is marketed. The other statements don’t fit because the FDA is indeed involved in drug safety, it regulates more than just advertisements, and its primary premarketing role isn’t limited to post-market safety.

Setting goals gives you the benchmarks for success in nursing care. When you plan, you decide what you want to achieve for the patient, and those goals establish clear criteria you will use to judge progress. The evaluation phase then looks at the patient’s actual status and asks: did we meet the goals, partially meet them, or miss them? This link makes evaluation purposeful—you're measuring against specific targets rather than checking random changes. Having specific, measurable goals makes evaluation objective. For example, a goal might be to reduce pain to a certain level within 48 hours or to improve mobility a set amount by a given day. During evaluation, you assess whether that target was reached, time-bound, and realistic, and you decide what to do next: continue the current plan, adjust interventions, or set new goals. If goals aren’t met, you reassess why and modify the plan. If goals are met, you continue to monitor to ensure maintenance or consider stepping down care. This dynamic relationship keeps nursing care focused, evidence-based, and patient-centered, and it applies across pharmacologic treatment as well, where evaluation includes observing therapeutic effects and adverse effects to determine if the medication is achieving the intended outcomes.

Teratogenic effects involve birth defects or developmental problems in a fetus caused by exposure to a drug or chemical during pregnancy, especially during early organ formation. A teratogenic reaction, then, is a reaction that produces congenital anomalies in the developing fetus due to such exposure. This is distinct from a general adverse effect (any undesired effect that may occur in the mother or fetus but isn’t specifically fetal development–related), from an idiosyncratic reaction (an unpredictable, unusual response), and from tolerance (a diminished effect with repeated dosing). Teratogenic risk depends on timing and dose, with examples including drugs like thalidomide, isotretinoin, or substances like alcohol causing fetal harm when exposure occurs in pregnancy.

Absorption in the GI tract hinges on processes that move the drug from the lumen into the bloodstream: how well the drug dissolves, how the environment affects its ability to stay non-ionized and permeate the mucosa, and how quickly and completely it reaches the bloodstream through adequate blood flow. The best predictor among the options is the level of consciousness, because it does not directly change these pharmacokinetic factors. Whether a person is awake or sleepy doesn’t alter the dissolution, ionization, or permeability of the drug once it’s in the GI tract; it mainly affects whether the medication can be swalled or requires an alternative route. In contrast, blood flow to the GI tract influences the driving force for absorption—more blood flow can carry absorbed drug away faster and maintain the concentration gradient, speeding absorption. Gastric pH changes the ionization state and solubility of many drugs, which can drastically alter how well they dissolve and are absorbed in different parts of the GI tract. Drug formulation determines how quickly and where the drug is released and dissolved (for example, immediate-release vs enteric-coated forms), shaping the overall absorption profile.